A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2002
12/10/2002	US6491924 Sequence of at least 5 consecutive amino acids in the polypeptide of seq id no: 1
12/10/2002	US6491921 Nucleic acids immunology vectors comprising eukaryotic transcription or translation gene expression controllers having enhancers and codes for immunogen polypeptides used against infections
12/10/2002	US6491920 Polypeptides and DNA encoding same
12/10/2002	US6491918 Antibody compositions for preparing enriched dendritic cell preparations
12/10/2002	US6491914 Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions including the anti-idiotypic monoclonal antibodies
12/10/2002	US6491913 For diagnosis and therapy of sulphamidase deficiency
12/10/2002	US6491907 Genetic engineered chimera particles comprising capsids from adeno-associated virus and genome inverted terminal repeat sequences as vectors for supplying and expressing nucleotide sequence in cells
12/10/2002	US6491906 CXC chemokines as regulators of angiogenesis
12/10/2002	US6491905 Recombinant bacterial cells for delivery of PNP to tumor cells
12/10/2002	US6491904 Topical composition containing human epidermal growth factor
12/10/2002	US6491893 Compounds for targeting and imaging infection and inflammation
12/10/2002	US6491391 System, apparatus, and method for reducing birefringence
12/10/2002	CA2239195C Ceramic packing with channels for thermal and catalytic beds
12/10/2002	CA2196085C Mhc complexes and uses thereof
12/10/2002	CA2121147C Synthetic lung surfactant having antioxidant properties
12/10/2002	CA2114015C Recombinant antibodies for human therapy
12/10/2002	CA2093431C Ionically cross-linked polymeric microcapsules
12/10/2002	CA2088574C Process for producing enzymes having superoxide dismutase activity, novel superoxide dismutase enzymes and novel pharmaceutical compositions comprising enzymes having superoxide dismutase activity
12/10/2002	CA2086925C New salts derived from dialkylaminoalkysulphonyl-26 pristinamycin iib
12/10/2002	CA2080182C Nuclear inhibitor i-92 and its use for the production of a medicament
12/10/2002	CA1341407C Minactivin
12/09/2002	WO2001096366A2 Dipeptide inhibitors for the blood-clotting factor xa
12/09/2002	CA2412181A1 Dipeptide inhibitors for the blood-clotting factor xa
12/08/2002	WO2003000892A1 Gene encoding b protein
12/08/2002	CA2817619A1 Methods of administering anti-tnf.alpha. antibodies
12/08/2002	CA2398093A1 Gene encoding protein b
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/07/2002	CA2386356A1 Ligation of ceacam1
12/06/2002	CA2349748A1 Therapeutic uses of glandular kallikrein
12/05/2002	WO2002097133A1 Antisense modulation of phospholipase a2, group iia (synovial) expression
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097116A2 Delivery system for nucleic acids
12/05/2002	WO2002097114A2 Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
12/05/2002	WO2002097110A2 TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF
12/05/2002	WO2002097108A2 Antisense modulation of dual specific phosphatase 5 expression
12/05/2002	WO2002097094A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
12/05/2002	WO2002097092A1 Neuronal cell-specific promoter
12/05/2002	WO2002097079A2 Gene encoding molecular motor protein and diagnosis method for the disease related to the gene
12/05/2002	WO2002097074A2 Human protein phosphatase 2c-like enzyme
12/05/2002	WO2002097073A2 Regulation of human phospholipase c delta-like enzyme
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097046A2 B7 related protein-2 molecules and uses thereof
12/05/2002	WO2002097044A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	WO2002097043A2 Wnv core protein/capsid interacting protein and uses of the same
12/05/2002	WO2002097042A2 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
12/05/2002	WO2002097037A2 Melanin-concentrating hormone analogs
12/05/2002	WO2002097036A2 Compositions and methods for adipose abundant protein
12/05/2002	WO2002097035A2 Secreted proteins
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096952A2 Conjugate of a transport protein and a protein for modulation of notch signalling
12/05/2002	WO2002096951A1 Molecules for disease detection and treatment
12/05/2002	WO2002096947A2 The lectin-like domain of thrombomodulin and its therapeutic use
12/05/2002	WO2002096946A1 Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy30
12/05/2002	WO2002096944A2 New heterotetrameric potassium channels and uses thereof
12/05/2002	WO2002096943A1 Stat6-activating genes
12/05/2002	WO2002096942A2 Recombinant dna encoding the major allergen of plantago lanceolata pollen pla l 1, and applications thereof
12/05/2002	WO2002096938A2 Human kunitz-type protease inhibitor
12/05/2002	WO2002096936A2 Daptomycin and related analogs in crystalline form, their preparation and use
12/05/2002	WO2002096935A2 Long lasting fusion peptide inhibitors for hiv infection
12/05/2002	WO2002096934A1 Non-natural galanin receptor ligands
12/05/2002	WO2002096933A1 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096930A2 Iap binding peptides and assays for identifying compounds that bind iap
12/05/2002	WO2002096927A2 Ribozyme based treatment of female reproductive diseases
12/05/2002	WO2002096926A1 Modulators of pharmacological agents
12/05/2002	WO2002096923A1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
12/05/2002	WO2002096910A1 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
12/05/2002	WO2002096903A2 Chemical derivatives and the use thereof as an anti-telomerase agent
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096468A2 Method for the diagnosis and therapy of renal cell carcinoma
12/05/2002	WO2002096467A2 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	WO2002096459A1 Tumor therapy
12/05/2002	WO2002096456A1 Use of il-18 inhibitors for treating or preventing cns injuries
12/05/2002	WO2002096454A1 Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
12/05/2002	WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	WO2002096428A1 Pharmaceutical combinations
12/05/2002	WO2002096398A2 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus
12/05/2002	WO2002096396A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein
12/05/2002	WO2002096390A1 Neutral-cationic lipid for systemic delivery of factor viii gene
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096356A2 HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
12/05/2002	WO2002096350A2 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
12/05/2002	WO2002096216A1 A method of improving the growth performance of an animal
12/05/2002	WO2002096195A1 Treatment or replacement therapy using transgenic stem cells delivered to the gut
12/05/2002	WO2002074247A3 Pharmaceutical formulations for sustained release
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002070546A3 Modified derivatives of cck-8
12/05/2002	WO2002068582A3 Phosphorothioate (p=s) oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002066043A3 Use of a polyfunctional active substance mixture as an antagonist against harmful substances contained in tobacco smoke
12/05/2002	WO2002064797A9 Mitochondrial topoisomerase i
12/05/2002	WO2002063018A8 Method for the production of plant seed with modified fibre content and modified seed coat
12/05/2002	WO2002062954A3 Antisense modulation of casein kinase 2-beta expression
12/05/2002	WO2002060420A3 Utilization of a claudin-4 ligand and conjugates thereof in the therapy and diagnosis of tumors
12/05/2002	WO2002059146A3 Peptides having affinity for the gp120 viral protein and use thereof
12/05/2002	WO2002056902A3 Ccr5 antagonist and dp-178 polypeptide for treating viral infections
12/05/2002	WO2002055675A8 Ancillary composition for the preparation of committed mature dendritic cells
12/05/2002	WO2002055553A3 Nucleotide sequences and protein(s) encoded by such nucleotides for modulation of apoptosis

1 ... 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 ... 3163